Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Z Gastroenterol
; 58(9): 841-846, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32947629
ABSTRACT
Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3â%) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Sulfonamidas
/
Carbamatos
/
Hepacivirus
/
Hepatite C Crônica
/
Compostos Macrocíclicos
/
Sofosbuvir
/
Compostos Heterocíclicos de 4 ou mais Anéis
Limite:
Humans
Idioma:
En
Revista:
Z Gastroenterol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Alemanha